Proteins and Peptides

22 Jun 2019 FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
22 Jun 2019 FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection)
21 Jun 2019 Esperoct® (turoctocog alfa pegol, N8-GP) approved in the EU
21 Jun 2019 Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly
21 Jun 2019 Medicenna Presents New Preclinical Results For its IL-2 Superkine Platform, MDNA109
21 Jun 2019 Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy
20 Jun 2019 Arch Biopartners Announces Start of Phase I Human Trial for Metablok
19 Jun 2019 Kleo Pharmaceuticals Announces a CD38 Targeting Antibody Recruiting Molecule (ARM™) to Treat Multiple Myeloma as the First Clinical Candidate in its Partnership with PeptiDream
19 Jun 2019 Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma
18 Jun 2019 Promedior Presents Positive Data from a Phase 2 Study of PRM-151 in Myelofibrosis Patients Failed/Ineligible for Ruxolitinib at the 24th European Hematology Association Annual Congress
18 Jun 2019 Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)
18 Jun 2019 FDA approves Victoza® for the treatment of type 2 diabetes in children and adolescents aged 10-17 years
13 Jun 2019 First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
13 Jun 2019 Noveome Biotherapeutics, Inc. Announces the First Patient Dosed in Phase 2 Open Label Clinical Trial Evaluating Topical Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defects
13 Jun 2019 Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
12 Jun 2019 OrthoTrophix Presents Clinical Data at European Congress of Rheumatology
12 Jun 2019 Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial
10 Jun 2019 Avacta Group plc Hits Clinical Candidate Selection Milestone for Affimer PD-L1 Inhibitor
10 Jun 2019 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog (insulin lispro), with superior post-meal blood glucose reductions
10 Jun 2019 Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments
09 Jun 2019 Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's 79ᵗʰ Scientific Sessions
09 Jun 2019 Dance Biopharm Presents Encouraging Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting
09 Jun 2019 Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks
07 Jun 2019 La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis
07 Jun 2019 Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up